Bayer presented results from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinic...
Global biopharmaceutical company Alvotech has announced that it has enrolled the first patient in its Phase III clinical...
Kezar Life Sciences, a South San Francisco-based clinical-stage biotechnology company discovering and developing n...
iSchemaView, the worldwide leader in advanced imaging for stroke care and research, is proud to announce that iSchemaVie...
Exicure, a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drug...
Foresee Pharmaceuticals, a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange has announced tha...
Enzychem Lifesciences, a global biopharmaceutical company headquartered in Seoul, Korea which is dedicated to developing...
Owlstone Medical, a diagnostics company developing a breathalyzer for applications in early disease detection and precis...
Sosei Group Corporation, has announced that the first healthy subject has been dosed with a novel small molecule HTL0030...
Mallinckrodt plc, a leading global specialty pharmaceutical company has announced interim analysis results of its compan...
Saniona, a biotech company focused on CNS and eating disorders has announced the successful completion of preclinical de...
Navitas Life Sciences, a TAKE Solutions Enterprise has announced that it will be acquiring Life Sciences services player...
Boehringer Ingelheim (Canada) Ltd. and IBM Canada have announced at the Healthcare Information and Management Systems So...
Pfizer Inc. and Astellas Pharma Inc. have announced the results from the Phase 3 ARCHES trial in men with metastatic hor...
The annual J.P. Morgan Healthcare Conference is the premier investor conference focused exclusively on companies definin...
Taiwan Liposome Company, a clinical-stage specialty pharmaceutical company dedicated to the development and commercializ...
Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase 3 clinical study ...
Spero Therapeutics, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ...
